Skip to main content
Insights into Imaging

Table 3 Systematic biopsies reduced versus csPCa detected and/or missed by cognitive MRTB in the development and validation cohorts using different biopsy strategies

From: Development and validation of a predictive model based on clinical and MpMRI findings to reduce additional systematic prostate biopsy

Threshold

Models

The development cohort (n = 201)

The validation cohort (n = 73)

No. of SB performed

No. of SB reduced

No. csPCa detected by MRTB

No. csPCa missed by MRTB

No. of SB performed

No. of SB reduced

No. csPCa detected by MRTB

No. csPCa missed by MRTB

50%

Clinical

105 (52.2%)

96 (47.8%)

99 (99%)

1 (1%)

53 (72.6%)

20 (27.4%)

32 (94.1%)

2 (5.9%)

MRI

98 (48.8%)

103 (51.2%)

98 (98%)

2 (2%)

39 (53.4%)

34 (46.6%)

33 (97.1%)

1 (2.9%)

Advanced

106 (52.7%)

95 (47.3%)

98 (98%)

2 (2%)

41 (56.2%)

32

33 (97.1%)

1 (2.9%)

60%

Clinical

105 (52.2%)

96 (47.8%)

99 (99%)

1 (1%)

53 (72.6%)

20 (27.4%)

32 (94.1%)

2 (5.9%)

MRI

108 (53.7%)

93 (46.3%)

98 (98%)

2 (2%)

39 (53.4%)

34 (46.6%)

33 (97.1%)

1 (2.9%)

Advanced

113 (56.2%)

88 (43.8%)

99 (99%)

1 (1%)

41 (56.2%)

32 (43.8%)

33 (97.1%)

1 (2.9%)

70%

Clinical

156 (77.6%)

45 (22.4%)

99 (99%)

1 (1%)

53 (72.6%)

20 (27.4%)

32 (94.1%)

2 (5.9%)

MRI

129 (64.2%)

72 (35.8%)

98 (98%)

2 (2%)

39 (53.4%)

34 (46.6%)

33 (97.1%)

1 (2.9%)

Advanced

130 (64.7%)

71 (35.3%)

99 (99%)

1 (1%)

48 (65.8%)

25 (34.2%)

33 (97.1%)

1 (2.9%)

80%

Clinical

187 (93.0%)

14 (7.0%)

100 (100%)

0 (0%)

53 (72.6%)

20 (27.4%)

32 (94.1%)

2 (5.9%)

MRI

175 (87.1%)

26 (12.9%)

100 (100%)

0 (0%)

48 (65.8%)

25 (34.2%)

33 (97.1%)

1 (2.9%)

Advanced

137 (68.2%)

64 (31.8%)

99 (99%)

1 (1%)

48 (65.8%)

25 (34.2%)

33 (97.1%)

1 (2.9%)

90%

Clinical

201 (100%)

0 (0%)

100 (100%)

0 (0%)

53 (72.6%)

20 (27.4%)

32 (94.1%)

2 (5.9%)

MRI

177 (88.1%)

24 (11.9%)

100 (100%)

0 (0%)

52 (71.2%)

21 (28.8%)

33 (97.1%)

1 (2.9%)

Advanced

164 (81.6%)

37 (18.4%)

100 (100%)

0 (0%)

49 (67.1%)

24 (32.9%)

33 (97.1%)

1 (2.9%)

–

PI-RADS 5

143 (71.1%)

58 (28.9%)

98 (98%)

2 (2%)

55 (75.3%)

18 (24.7%)

33 (97.1%)

1 (2.9%)

  1. Note: Data in percentages are percentages of all performed additional systematic biopsies or all clinically significant prostate cancers (csPCas) detected by cognitive MRI-target biopsy
  2. PI-RADS Prostate Imaging Reporting and Data System, MRTB MRI-targeted biopsy, SB systematic biopsy
Back to article page